Lewis Y regulates signaling molecules of the transforming growth factor β pathway in ovarian carcinoma-derived RMG-I cells

Li,Fei-Fei; Liu,Juan-Juan; Liu,Da-Wo; Lin,Bei; Hao,Ying-Ying; Cong,Jian-Ping; Zhu,Lian-Cheng; Gao,Song; Zhang,Shu-Lan; Iwamori,Masao

doi:10.3892/ijo.2011.1296

Lewis Y regulates signaling molecules of the transforming growth factor β pathway in ovarian carcinoma-derived RMG-I cells

Authors:
- Fei-Fei Li
- Juan-Juan Liu
- Da-Wo Liu
- Bei Lin
- Ying-Ying Hao
- Jian-Ping Cong
- Lian-Cheng Zhu
- Song Gao
- Shu-Lan Zhang
- Masao Iwamori
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang 110004, P.R. China, Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang 110004, Liaoning Province, P.R. China
Published online on: December 13, 2011 https://doi.org/10.3892/ijo.2011.1296
Pages: 1196-1202

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

LeY (Lewis Y) is a difucosylated oligosaccharide carried by glycoconjugates on the cell surface. Elevation of LeY is frequently observed in epithelial-derived cancers and is correlated to pathological staging and prognosis. To study the role of LeY on cancer cells, a stably LeY-overexpressing cell line, RMG-I-H, was developed previously by transfection of the α1,2-fucosyltransferase gene, a key enzyme that catalyzes the synthesis of LeY, into ovarian carcinoma-derived RMG-I cells. Our studies have shown that LeY is involved in the changes in biological behavior of RMG-I-H cells. However, the mechanism is still largely unknown. In this study, we determined the structural relationship and co-localization between LeY and TβRI/TβRII, respectively, and the potential cellular signaling mechanism was also investigated. We found that both TβRI and TβRII contain the LeY structure, and the level of LeY in TβRI and TβRII in RMG-I-H cells was significantly increased. Overexpression of LeY up-regulates the phosphorylation of ERK, Akt and down-regulates the phosphorylation of Smad2/3. In addition, the phosphorylation intensity was attenuated significantly by LeY monoantibody. These findings suggest that LeY is involved in the changes in biological behavior through TGF‑β receptors via Smad, ERK/MAPK and PI3K/Akt signaling pathways. We suggest that LeY may be an important composition of growth factor receptors and could be an attractive candidate for cancer diagnosis and treatment.

View Figures

View References

1	Baldus SE, Mönig SP, Zirbes TK, et al: Lewis(y) antigen (CD174) and apoptosis in gastric and colorectal carcinomas: correlations with clinical and prognostic parameters. Histol Histopathol. 21:503–510. 2006.PubMed/NCBI
2	Kuemmel A, Single K, Bittinger F, et al: The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer. Tumour Biol. 28:340–349. 2007. View Article : Google Scholar : PubMed/NCBI
3	Chhieng DC, Rodriguez-Burford C, Talley LI, et al: Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma. Hum Pathol. 34:1016–1021. 2003. View Article : Google Scholar : PubMed/NCBI
4	Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I and Durrant LG: High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res. 7:R780–R787. 2005. View Article : Google Scholar : PubMed/NCBI
5	Iwamori M, Tanaka K, Kubushiro K, et al: Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the α1,2-fucosyltransferase gene. Cancer Sci. 96:26–30. 2005.PubMed/NCBI
6	Lin B, Hao YY, Wang DD, Zhu LC, Zhang SL, Saito M and Iwamori M: Transfection of α1,2-fucosyltransferase gene increases the antigenic expression of Lewis y in ovarian cancer cell line RMG-I. Acta Acad Med Sin. 30:284–289. 2008.
7	Hao YY, Lin B, Zhao Y, et al: Alpha1,2-fucosyltransferase gene transfection influences on biological behavior of ovarian carcinoma-derived RMG-I cells. Fen Zi Xi Bao Sheng Wu Xue Bao. 41:435–442. 2008.
8	Liu J, Lin B, Hao Y, et al: Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 28:1542009. View Article : Google Scholar
9	Li F, Lin B, Hao Y, et al: Lewis y promotes growth and adhesion of ovarian carcinoma-derived RMG-I cells by upregulating growth factors. Int J Mol Sci. 11:3748–3759. 2010. View Article : Google Scholar : PubMed/NCBI
10	Wang X, Inoue S, Gu J, et al: Dysregulation of TGF-β1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci USA. 102:15791–15796. 2005.
11	Zhu LC, Lin B, Hao YY, Li FF, Diao B and Zhang SL: Impact of α1,2-fucosyltransferase gene transfection on cancer-related gene expression profile of human ovarian cancer cell line RMG-1. Ai Zheng. 27:934–941. 2008.
12	Basu A, Murthy U, Rodeck U, Herlyn M, Mattes L and Das M: Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas. Cancer Res. 47:2531–2536. 1987.PubMed/NCBI
13	Klinger M, Farhan H, Just H, et al: Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res. 64:1087–1093. 2004. View Article : Google Scholar : PubMed/NCBI
14	Kosunen TU, Bång BE and Hurme M: Analysis of Campylobacter jejuni antigens with monoclonal antibodies. J Clin Microbiol. 19:129–133. 1984.
15	Bång BE, Hurme M, Juntunen K and Mäkelä O: Studies of monoclonal and polyclonal anti-digoxin antibodies for serum digoxin radioimmunoassay. Scand J Clin Lab Invest. 41:75–78. 1981.PubMed/NCBI
16	Moran AP, Knirel YA, Senchenkova SN, Widmalm G, Hynes SO and Jansson PE: Phenotypic variation in molecular mimicry between Helicobacter pylori lipopolysaccharides and human gastric epithelial cell surface glycoforms. Acid-induced phase variation in Lewisx and Lewisy expression by H pylori lipopolysaccharides. J Biol Chem. 277:5785–5795. 2002.PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Yu L, Hébert MC and Zhang YE: TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J. 21:3749–3759. 2002.
19	Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature. 425:577–584. 2003.
20	Wilkes MC, Mitchell H, Penheiter SG, et al: Transforming growth factor-β activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res. 65:10431–10440. 2005.
21	Zhang YE: Non-Smad pathways in TGF-β signaling. Cell Res. 19:128–139. 2009.
22	Pasche B: Role of transforming growth factor beta in cancer. J Cell Physiol. 186:153–168. 2001. View Article : Google Scholar : PubMed/NCBI
23	Elliott RL and Blobe GC: Role of transforming growth factor beta in human cancer. J Clin Oncol. 23:2078–2093. 2005. View Article : Google Scholar : PubMed/NCBI
24	Tian M and Schiemann WP: The TGF-β paradox in human cancer: an update. Future Oncol. 5:259–271. 2009.
25	Fynan TM and Reiss M: Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncol. 4:493–540. 1993.PubMed/NCBI
26	Massagué J, Blain SW and Lo RS: TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 103:295–309. 2000.
27	Yamada SD, Baldwin RL and Karlan BY: Ovarian carcinoma cell cultures are resistant to TGF-β1-mediated growth inhibition despite expression of functional receptors. Gynecol Oncol. 75:72–77. 1999.PubMed/NCBI
28	Hu W, Wu W, Nash MA, Freedman RS, Kavanagh JJ and Verschraegen CF: Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines. Anticancer Res. 20:729–733. 2000.PubMed/NCBI
29	Chang J, Park K, Bang YJ, Kim WS, Kim D and Kim SJ: Expression of transforming growth factor β type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res. 57:2856–2859. 1997.
30	Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J and Markowitz S: Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 58:3101–3104. 1998.
31	Hahn SA, Schutte M, Hoque AT, et al: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:350–353. 1996. View Article : Google Scholar : PubMed/NCBI
32	Miyaki M, Iijima T, Konishi M, et al: Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene. 18:3098–3103. 1999. View Article : Google Scholar : PubMed/NCBI
33	Eppert K, Scherer SW, Ozcelik H, et al: MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 86:543–552. 1996.PubMed/NCBI
34	Wang D, Kanuma T, Takama F, et al: Mutation analysis of the smad3 gene in human ovarian cancers. Int J Oncol. 15:949–953. 1999.PubMed/NCBI
35	Vincent F, Nagashima M, Takenoshita S, Khan MA, Gemma A, Hagiwara K and Bennett WP: Mutation analysis of the transforming growth factor-β type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-β. Oncogene. 15:117–122. 1997.
36	Wang D, Kanuma T, Mizumuma H, Ibuki Y and Takenoshita S: Mutation analysis of the Smad6 and Smad7 gene in human ovarian cancers. Int J Oncol. 17:1087–1091. 2000.PubMed/NCBI
37	Dettke M, Pálfi G and Loibner H: Activation-dependent expression of the blood group-related lewis Y antigen on peripheral blood granulocytes. J Leukoc Biol. 68:511–514. 2000.PubMed/NCBI
38	Farhan H, Schuster C, Klinger M, et al: Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. J Pharmacol Exp Ther. 319:1459–1466. 2006. View Article : Google Scholar : PubMed/NCBI
39	Wang QY, Zhang Y, Chen HJ, Shen ZH and Chen HL: Alpha 1,3-fucosyltransferase-VII regulates the signaling molecules of the insulin receptor pathway. FEBS J. 274:526–538. 2007. View Article : Google Scholar : PubMed/NCBI
40	Dowdy SC, Mariani A and Janknecht R: HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor β inhibitor Smad7 via the ETS protein ER81. J Biol Chem. 278:44377–44384. 2003.PubMed/NCBI
41	Ohashi N, Yamamoto T, Uchida C, et al: Transcriptional induction of Smurf2 ubiquitin ligase by TGF-β. FEBS Lett. 579:2557–2563. 2005.
42	Edlund S, Bu S, Schuster N, et al: Transforming growth factor-β1 (TGF-β)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-β-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell. 14:529–544. 2003.
43	Iwai T, Murai J, Yoshikawa H and Tsumaki N: Smad7 inhibits chondrocyte differentiation at multiple steps during endochondral bone formation and down-regulates p38 MAPK pathways. J Biol Chem. 283:27154–27164. 2008. View Article : Google Scholar : PubMed/NCBI
44	Mazars A, Lallemand F, Prunier C, et al: Evidence for a role of the JNK cascade in Smad7-mediated apoptosis. J Biol Chem. 276:36797–36803. 2001. View Article : Google Scholar : PubMed/NCBI